New hope for tough ovarian cancer? drug combo trial begins
Disease control
Recruiting now
This early-phase study tests a new drug (DT2216) combined with standard chemotherapy (paclitaxel) in 30 people with ovarian cancer that has returned and is resistant to platinum-based treatments. The main goal is to find the safest dose of DT2216 when given with paclitaxel, and t…
Phase: PHASE1 • Sponsor: Elizabeth Stover, MD, PhD • Aim: Disease control
Last updated May 11, 2026 20:47 UTC